Shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS) fell sharply during Friday's session after the company announced plans to raise fresh capital.Intelligent Bio said it will raise $10 million through a private placement, which weighed on shares following the announcement.Intelligent Bio Solutions shares dipped 19.7% to $7.65 on Friday.Here are some other stocks moving in today’s mid-day session.GainersLavoro Limited (NASDAQ:LVRO) jumped 181% to $1.2900.Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) rose 5 ...

| 代码 | 名称 | 最新价 | 涨跌幅 ^ | 涨跌额 | 成交额 | | --- | --- | --- | --- | --- | --- | | WOK | 沃氪医疗 | 0.0328 | -32.92% | -0.0161 | 286.45万 | | BVC | BitVentures | 1.200 | -21.57% | -0.330 | 51.28万 | | OCG | 东方文化 | 0.0911 | -13.57% | -0.0143 | 128.3万 | | VSA | 童程童美 | 2.760 | -13.48% | -0.430 | 21.24万 | | MENS | 健永生技 | 3.560 | -11.44% | -0.460 | 327.77万 | 中概股收盘跌幅居前的个股为：沃氪医疗跌32.92%，BitVentures跌21.57%，东方文化跌13.57%，童程童 美跌13.48%，健永生技跌11.44%。(格隆汇) ...

Group 1 - U.S. stock futures were mostly flat, with Nasdaq 100 futures slipping around 0.01% [1] - Sidus Space, Inc. announced a public offering of 19,230,800 shares at $1.30 per share, leading to a 39.2% decline in its shares to $1.39 in pre-market trading [1] Group 2 - Starfighters Space Inc shares dipped 23.2% to $24.19 after a significant gain of over 370% on Monday [2] - ECD Automotive Design, Inc. fell 15.4% to $0.1650 following a 1-for-5 reverse stock split announcement [2] - CapsoVision Inc dipped 5.6% to $12.35, while Rocket Lab Corp fell 5.3% to $73.46 after a previous 10% jump [2] - Intuitive Machines Inc declined 5.2% to $15.82 despite a price target increase from $14 to $20 by B. Riley Securities [2] - Firefly Aerospace Inc shares declined 4.4% to $27.33 after a 16% increase due to joining the Russell 2000 and Russell 3000 indexes [2] - AST SpaceMobile Inc shares declined 3.1% to $83.82 after a 14% surge related to new satellite details [2]

中概股收盘涨幅居前的个股为：昊鑫控股涨273.91%，美华创富涨70.41%，健永生技涨50.55%，中驰车 福涨32.8%，拍明芯城涨28%。(格隆汇) | 代码 | 名称 | 最新价 | 涨跌幅 V | 涨跌额 | 成交额 | | --- | --- | --- | --- | --- | --- | | HXHX | 吴塞控股 | 1.2900 | 273.91% | +0.9450 | 2.7亿 | | MGRT | 美华创富 | 12.440 | 70.41% | +5.140 | 468.87万 | | MENS | 健永生技 | 4.780 | 50.55% | +1.605 | 1.24亿 | | AZI | 中驰车福 | 3.320 | 32.80% | +0.820 | 1.63亿 | | IZM | 拍明芯城 | 1.600 | 28.00% | +0.350 | 125.84万 | ...

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Monday.Following the market opening Monday, the Dow traded up 0.18% to 48,222.17 while the NASDAQ jumped 0.56% to 23,439.24. The S&P 500 also rose, gaining, 0.45% to 6,864.96.Check This Out: GE Vernova To Rally Around 26%? Here Are 10 Top Analyst Forecasts For MondayLeading and Lagging SectorsEnergy shares rose by 1.3% on Monday.In trading on Monday, utilities stocks fell by 0.5%.Top HeadlineThe Chicago Fed Nat ...

Core Viewpoint - Jyong Biotech Ltd. is experiencing fluctuations in its share price and increased trading volume following the expiry of the lock-up period, while engaging with investment funds interested in purchasing its shares [1]. Company Overview - Jyong Biotech Ltd. is a biotechnology company based in Taiwan, focused on developing and commercializing innovative plant-derived drugs, particularly for urinary system diseases, with a target market in the U.S., EU, and Asia [6]. - The company has established integrated capabilities across all key functionalities of drug development since its inception in 2002, including drug discovery, clinical trials, and commercialization [6]. Financial and Operational Status - The company's research and development operations remain solid, and its financial condition is consistent with recent public filings, including the Current Report on Form 6-K [3]. - Jyong Biotech has completed four Phase III clinical trials in the U.S. and Taiwan, along with one Phase II clinical trial in Taiwan, and is advancing its investigational pipeline [5]. Strategic Developments - The company holds global multi-country invention patents, providing market protection across the Americas, Asia, and Europe, and has signed Letters of Intent (LOIs) with several international pharmaceutical companies [5]. - Jyong Biotech is committed to expanding its global presence and aims to deliver world-class botanical new drugs to address significant unmet medical needs [5]. Compliance and Disclosure - The company confirms compliance with SEC regulations and is not aware of any material, unpublished price-sensitive information that would explain the recent trading activity [2][4].

| 代码 | 名称 | 最新价 | 涨跌幅 ^ | 涨跌额 | 成交额 | | --- | --- | --- | --- | --- | --- | | MENS | 健永生技 | 2.920 | -81.04% | -12.480 | 1314.86万 | | AEHL | 羚羊控股 | 1.790 | -25.73% | -0.620 | 44.57万 | | MASK | 3 E Network Technolo | 0.2620 | -22.96% | -0.0781 | 77.66万 | | TC | Token Cat | 12.000 | -21.77% | -3.340 | 104.89万 | | EDHL | Everbright Digital | 0.4515 | -17.49% | -0.0957 | 25.71万 | 中概股收盘跌幅居前的个股为：健永生技跌81.04%，羚羊控股跌25.73%，3 E Network Technolo跌 22.96%，Token Cat跌21.77%，Everbright Digital跌17.49%。(格隆汇) ...

Group 1 - The core point of the article highlights significant declines in the stock prices of several Chinese concept stocks, with CIMG experiencing the largest drop of 31.98% [1] - CIMG's latest price is reported at 1.170, with a decrease of 0.550 and a trading volume of 1.7132 million [1] - Other notable declines include MENS down 31.22% to 15.400, CGTL down 18.63% to 0.952, NCRA down 18.60% to 1.050, and MASK down 17.05% to 0.3401 [1][1][1] Group 2 - The trading volume for MENS was 6.5639 million, while CGTL had a trading volume of 1.1541 million [1] - NCRA's trading volume was 0.4163 million, and MASK's trading volume was 1.8397 million [1][1]

Core Viewpoint - Jyong Biotech Ltd. has entered into a non-binding Memorandum of Understanding (MOU) with a Vietnam-based pharmaceutical distribution company to explore the development and commercialization of MCS-2 in the Vietnamese pharmaceutical market [1][2]. Group 1: MOU Details - The MOU outlines that both parties will conduct due diligence and discussions to define the scope and structure of any potential collaboration, including commercial strategy, regulatory pathway, and local market execution [2]. - There is no guarantee that a definitive agreement will be reached or that the collaboration will be finalized [2]. Group 2: Strategic Importance - The CEO of Jyong Biotech emphasized that this MOU is a significant step in the company's Asia-focused strategy to introduce plant-derived MCS therapies to new markets, highlighting Vietnam's potential for patient access and local partnerships [3]. - This MOU follows a previously announced non-binding Letter of Intent with a South Korean pharmaceutical company to explore in-licensing and development opportunities for plant-derived MCS products [3]. Group 3: Product Status - MCS-2 is currently an investigational new drug candidate and has not yet received approval for commercial use in any jurisdiction [4]. Group 4: Company Overview - Jyong Biotech Ltd. is a science-driven biotechnology company based in Taiwan, focusing on developing and commercializing innovative plant-derived drugs, particularly for urinary system diseases, with initial market focus on the U.S., EU, and Asia [5]. - Since its establishment in 2002, the company has developed integrated capabilities across all key drug development functions, including early-stage drug discovery, clinical trials, regulatory affairs, manufacturing, and commercialization [5].

Core Viewpoint - Jyong Biotech Ltd. has entered into a non-binding letter of intent with a South Korean pharmaceutical company to explore the potential in-licensing and development of its plant-derived new drug MCS-2 for the Korean market [1][2] Group 1: Company Overview - Jyong Biotech Ltd. is a science-driven biotechnology company based in Taiwan, focused on developing and commercializing innovative plant-derived drugs, particularly for urinary system diseases, targeting markets in the U.S., EU, and Asia [1][4] - The company has been operational since 2002 and has developed integrated capabilities across drug discovery, clinical trials, regulatory affairs, manufacturing, and commercialization [4] - Jyong Biotech is advancing several botanical drug candidates, including its primary candidate BOTRESO® and other clinical and preclinical-stage candidates [4] Group 2: Strategic Partnership - The engagement with the South Korean pharmaceutical company aligns with Jyong Biotech's co-commercialization strategy, aiming to leverage the partner's established sales networks and local regulatory expertise [2] - The partnership, if finalized, is expected to enhance market access and patient reach in Korea by utilizing the partner's commercial infrastructure [2][3] - The letter of intent is non-exclusive and subject to due diligence, regulatory review, and negotiation of definitive agreements [2] Group 3: Product Development Status - MCS-2 is currently an investigational new drug candidate and has not yet received approval for commercial use in any jurisdiction [3] - The company is committed to complying with regulatory disclosure obligations and will provide updates on material developments as they occur [3]